![Anne Erickson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anne Erickson
Corporate Officer/Principal presso
SAVARA INC.
Patrimonio netto: 2 M $ in data 30/09/2026
Profilo
Anne C.
Erickson is currently Chief Business Officer at Savara, Inc., a position held since 2023.
Formerly, Ms. Erickson was Executive Director-Investor & Media Relations at Halozyme Therapeutics, Inc. Ms. Erickson completed undergraduate studies at the University of Minnesota.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
SAVARA, INC. 0,18% | 14/12/2025 | 371.712 ( 0,18% ) | 2 M $ | 30/09/2026 |
Posizioni attive di Anne Erickson
| Società | Posizione | Inizio |
|---|---|---|
| SAVARA INC. | Corporate Officer/Principal | 01/10/2022 |
Precedenti posizioni note di Anne Erickson
| Società | Posizione | Fine |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | - |
Formazione di Anne Erickson
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
28
Relazioni di 1° grado
3
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Savara, Inc.
 Savara, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals to treat respiratory diseases | Health Technology |
